Technology evaluation: CpG-7909, Coley
Paul, S.ép.
Current Opinion in Molecular Therapeutics 5(5): 553-559
2003
ISSN/ISBN: 1464-8431 PMID: 14601526 Document Number: 553417
Coley Pharmaceutical (formerly CpG ImmunoPharmaceuticals) is developing CpG-7909 (ProMune) for use in the potential treatment of cancer and as a vaccine adjuvant. By April 2000, CpG-7909 had entered phase I/II trials for cancer and in March 2002, Coley initiated a phase I trial in non-Hodgkin's lymphoma in combination with rituximab (Rituxan). By October 2002, CpG-7909 was in phase II trials as a vaccine adjuvant. Cpg-7909 is currently also undergoing phase II trials for melanoma.